scholarly journals Gene expression profiles reveal that chondrogenic progenitor cells and synovial cells are closely related

2014 ◽  
Vol 32 (8) ◽  
pp. 981-988 ◽  
Author(s):  
Cheng Zhou ◽  
Hongjun Zheng ◽  
Dongrim Seol ◽  
Yin Yu ◽  
James A. Martin
Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4162-4162
Author(s):  
Andrew A.G. Aprikyan ◽  
David Pritchard ◽  
Conrad W. Liles ◽  
Steve Schwartz ◽  
David C. Dale

Abstract G-CSF is widely used to accelerate marrow recovery after cancer chemotherapy, to facilitate collection of hematopoietic progenitor cells, and to treat severe chronic neutropenia. Although G-CSF was originally defined as a stimulus for myeloid cell proliferation, it has potent anti-apoptotic properties, affects synthesis of proteins stored in neutrophil granules, and has many other effects on cells of the myeloid lineage. To improve understanding of the molecular and cellular effects of G-CSF, particularly related to its use for the treatment of severe chronic neutropenia, we performed gene expression profile studies using Affymetrix oligonucleotide arrays and purified bone marrow cell sub-populations from normal volunteers treated with daily subcutaneous G-CSF (300 mcg/sc/qd) for five days. Under local anaesthesia, paired marrow aspirates were obtained from the posterior iliac crest before and after 5 daily doses of G-CSF. CD34+ and CD34−/CD33+ cells were purified using Miltenyi immunomagnetic beads. Two rounds of amplification of total RNA isolated from purified CD34+ or CD33+cells was used to obtain sufficient cRNA for hybridization. Expression data from scanned chips were first analyzed using the RMA algorithm. The limma package of the Bioconductor project was used to identify differentially expressed genes. Limma uses an empirical Bayes method to moderate the standard errors of the estimated log-fold changes. The statistical analysis of CD33+ cells revealed that 150 of more than 12,000 genes examined were up- or down-regulated >2-fold in response to G-CSF treatment. The top 10 genes with up- or down-regulated level of expression include clusterin, neutrophil elastase, two transcription factors, gelsolin, Grb2, phospholipase D3, protein kinase C, the major vault protein, and serine-threonine kinase. In the myeloid-committed CD34-/CD33+ progenitor cells, genes with altered expression level represent those with gene products involved in the cell cycle, regulation of apoptosis, the cytoskeleton, the inflammatory response, or serine proteases and transcription factors. Most of the genes up-regulated in CD33+ cells (e.g. neutrophil elastase, phospholipase D, protein kinase C) were down-regulated in CD34-positive cells in response to G-CSF. The results of the comparative analyses revealed the normal signature gene expression profiles for CD34+ and CD34−/CD33+ cells and identified genes that may mediate specific G-CSF effects.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 394-394
Author(s):  
Marc J. Braunstein ◽  
Daniel R. Carrasco ◽  
Fabien Campagne ◽  
Piali Mukherjee ◽  
Kumar Sukhdeo ◽  
...  

Abstract Background: In multiple myeloma (MM), bone-marrow-derived endothelial progenitor cells (EPCs) contribute to tumor neoangiogenesis, and their levels covary with tumor mass and prognosis. Recent X-chromosome inactivation studies showed that EPCs are clonally restricted in MM. In addition, high-resolution array comparative genomic hybridization (aCGH) found that the genomes of EPCs and MM cells display similar chromosomal gains and losses in the same patient. In this study, we performed an integrative analysis of EPCs and tumor cells by genome-wide expression profiling, and applied a bioinformatics approach that leverages gene expression data from cancer datasets to mine MM gene pathways common to multiple tumor tissues and likely involved in MM pathogenesis. Methods: Confluent EPCs (>98% vWF/CD133/KDR+ and CD38−) were outgrown from 22 untreated MM patients’ bone marrow aspirates by adherence to laminin. The fractions enriched for tumor cells were >50% CD38+. For gene expression profiling, total RNA from EPCs, MM cells, and control HUVECs were hybridized to cDNA microarrays, and comparisons were made by analysis of variance. Results: Two sets of EPC gene profiles were of particular interest. The first contained genes that differ significantly between EPCs and HUVEC, but not between EPCs and tumor (Profile 1). We hypothesize that this profile is a consequence of the clonal identity previously reported between EPCs and tumor, and that a subset of these genes is largely responsible for MM progression. The second set of important EPC genes are differentially regulated compared both to HUVECs and to tumor cells (Profile 2). These genes may represent the profile of EPCs that are clonally diverse from tumor cells but nevertheless display common gene expression patterns with other cancers. Profile 2 genes may also represent genes that confer a predisposition to clonal transformation of EPCs. When genes in Profile 1 and Profile 2 were overlapped with published lists of cancer biomarkers, significant similarities (P<.05) were apparent. The largest overlaps were observed with the HM200 gene list, a list composed of 200 genes most consistently differentially expressed in human/mouse cancers (Campagne and Skrabanek, BMC Bioinformatics 2006). More than 80% of genes in either EPC profile have not been previously characterized in MM, but have been identified as cancer biomarkers in other cancer studies. These genes will be presented and discussed in the context of MM. Current studies are aimed at integrating Profile 1 and Profile 2 genes in each patient with chromosomal copy number abnormalities (CNAs) found in EPCs, and also with clinical stage and disease severity, in order to elucidate the pathogenic information that the profiles hold. Conclusions: The genomes of EPCs display ranges of overlap with tumor cells in MM, evidenced by gene expression profiles with varying similarity to those found in MM tumor cells. More importantly, MM EPC gene expression profiles, in contrast to normal endothelial cells, contain cancer biomarker genes in tumors not yet associated with MM. Results strongly support the concept that EPCs are an integral part of the neoplastic process in MM.


2012 ◽  
Vol 8 (4) ◽  
pp. 1163-1177 ◽  
Author(s):  
Srilatha Jasty ◽  
Priyadharashni Srinivasan ◽  
Gunisha Pasricha ◽  
Nivedita Chatterjee ◽  
Krishnakumar Subramanian

2017 ◽  
Vol 6 (12) ◽  
pp. 2942-2956 ◽  
Author(s):  
Sócrates Avilés-Vázquez ◽  
Antonieta Chávez-González ◽  
Alfredo Hidalgo-Miranda ◽  
Dafne Moreno-Lorenzana ◽  
Lourdes Arriaga-Pizano ◽  
...  

2007 ◽  
Vol 21 (5) ◽  
Author(s):  
Young‐Ae Kim ◽  
Sung Lyea Park ◽  
Wonhee Suh ◽  
Byoung‐Hyun Min ◽  
Chang‐Hyun Moon ◽  
...  

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1605-1605
Author(s):  
Akihito Shinohara ◽  
Yoichi Imai ◽  
Masahiro Nakagawa ◽  
Tsuyoshi Takahashi ◽  
Motoshi Ichikawa ◽  
...  

Abstract Abstract 1605 Reactive oxygen species (ROS) are small molecules containing oxygen with unpaired electron. ROS are always generated as the products of cellular metabolism, and cells have several antioxidant systems to avoid their harmful effect induced by their high chemical reactivity. While studies about biological effects of ROS have been mainly focused on the harmful aspects, a growing body of evidence suggests that ROS are critical mediators of several signaling pathways in cellular homeostasis. In hematopoiesis, for example, it was reported that the generation of intracellular ROS functions as the initiation signal in the development of Drosophila hematopoietic cells and that ROS control self-renewal of hematopoietic stem cells. However, little is known about the functions of ROS in regulating hematopoietic progenitors. In this study, we show a critical role of ROS in lineage decision of myeloid progenitor cells. Firstly, we measured the intracellular ROS level of hematopoietic cells from murine bone marrow by flow cytometry with H2-DCFDA (2’,7’-dichlorofluorescin diacetate) staining. It was found that intracellular ROS level of megakaryocyte-erythrocyte progenitor cells (MEP) was kept equal to or lower than that of lineage marker negative, Sca-1 positive, c-Kit positive (KSL) cells. On the other hand, that of granulocyte-monocyte progenitor cells (GMP) was significantly elevated. Additionally, mRNA expression of NADPH oxidase 2 (cytochrome b-245) and NOXA2 (neutrophil cytosolic factor 2), both of which are major components of the membrane-bound oxidase complex generating ROS in cells, was significantly suppressed in MEP and KSL cells, whereas it was up-regulated in GMP. Thus, intracellular ROS level of MEP is kept lowest in hematopoietic cells. Next, we investigated the effect of ROS on the differentiation of myeloid progenitors. In liquid culture assay, loading of ROS with low dose hydrogen peroxide inhibited the differentiation of progenitor cells into MEP, whereas removal of ROS with catalase accelerated the differentiation of those into MEP. Similarly, in the colony-forming assay with semisolid culture medium, we observed that loading of ROS inhibited the formation of megakaryocyte-erythrocyte colonies. To investigate the effect of intrinsic ROS on the colony-forming capacity, we sorted ROS-high and low common myeloid progenitor cells (CMP) individually and cultured them. It was shown that ROS-low CMP had high colony-forming capacity of megakaryocyte-erythrocyte, whereas ROS-high CMP had high colony-forming capacity of granulocyte-monocyte. There is inverse correlation between intracellular ROS level of CMP and colony-forming capacity of megakaryocyte-erythrocyte. In order to confirm that ROS can control the differentiation of CMP into MEP or GMP in vivo, we injected lipopolysaccharide (LPS), which can increase intracellular ROS level of bone marrow cells, into mice. We found that MEP were decreased in LPS-injected mice. Finally, we performed gene expression microarray analysis to compare gene expression profiles between ROS-low and high CMP. In terms of gene expression profiles, ROS-low CMP were similar to MEP and magakaryocyte whereas ROS-high CMP were similar to GMP. In conclusion, these findings suggest that intracellular ROS play a critical role in lineage decision of myeloid progenitor cells, especially in the generation of MEP. In several diseases with anemia or thrombocytopenia, such as myelodysplastic syndrome, Fanconi anemia and autoimmune diseases with chronic inflammation, it was reported that intracellular ROS level of hematopoietic cells was up-regulated. Thus, up-regulated intracellular ROS may be involved in their symptoms via differentiation disorder of MEP. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3646-3646
Author(s):  
Kirsten Heitmann ◽  
Zhe Li ◽  
Jan-Henning Klusmann ◽  
Basant Kumar Thakur ◽  
Jennifer Schöning ◽  
...  

Abstract Abstract 3646 Children with Down syndrome (DS) are at high risk to develop acute megakaryoblastic leukemia (DS-AMKL) and the antecedent transient leukemia (DS-TL). Acquired mutations in the hematopoietic transcription factor GATA1, leading to expression of a shorter GATA1 variant (referred to as GATA1s) truncated at its N-terminus, are consistently present in the affected cells of children with DS-AMKL and DS-TL. Mechanistically, we recently found that in fetal megakaryocytic progenitor cells, GATA1 coordinates proliferation and differentiation by repressing E2F target genes through a direct interaction with E2F activators. Failure of this GATA1-E2F interaction in mutated GATA1s likely converges with overactive IGF signaling to promote cellular transformation. The treatment of DS-AMKL is hampered by their sensitivity against current cytostatic agents, resulting in treatment-related mortality as the main cause of death. To develop novel targeted and less toxic treatment options for DS-AMKL and DS-TL, we conducted a gene expression-based chemical genomic screen. We connected a DS-AMKL gene expression signature (compared to non-DS-AMKL, i.e. GATA1s vs. GATA1) to a reference collection of gene-expression profiles from cultured human cells treated with bioactive small molecules (Connectivity Map). We discovered the histone deacetylase (HDAC) inhibitor valproic acid (VPA) reverses the DS-AMKL gene expression program. Cell viability assays, cell cycle analyses, growths curves and colony-forming assays revealed exceptional sensitivity of DS-AMKL cell lines (CMK, CMY; IC50 1mM) and primary DS-AMKL and DS-TL blasts to VPA treatment compared to control cell lines K562 (IC50 4.75mM), M07 (IC50 6.75mM) and CD34+ hematopoietic stem and progenitor cells (IC50 4.75mM). VPA induces apoptosis (26.8% 7-AAD-)Annexin V+ and 38.8% 7-AAD+ CMK cells after 48h at 2mM VPA) and cell cycle arrest (50% reduction of CMK cells in S-phase at 2mM) via activation of the cell cycle inhibitor p21 and the proapoptotic genes BAX and BAK. Gene expression profiles indicated that VPA interferes with the oncogenic effects of GATA1s by globally repressing the deregulated E2F targets. The effects of VPA on leukemic growth in DS-AMKL could be attributed to its HDAC inhibitory function, as the global HDAC inhibitors SAHA and TSA induced a similar response. Thus, by using a gene expression-based chemical genomic approach, we identified VPA as an efficient and well-tolerated treatment option for DS-AMKL and DS-TL by targeting GATA1s-mediated deregulation of the E2F transcription network. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document